GlassScriptPhysician profile
Kristin D King
NPI 1730526328
$9,467.94
in general payments reported to CMS, 2019-2025
58 companies · $1,766 in 2025
The $1,766 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,634 · 2020: $786 · 2021: $374 · 2022: $728 · 2023: $1,432 · 2024: $1,750 · 2025: $1,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,736 · Consulting Fee: $150 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,735.93 |
| Consulting Fee | $150.00 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,141.83 | 2019-2025 | |
| Ucb, INC. | $546.36 | 2019-2025 | Briviact, Nayzilam |
| Novartis Pharmaceuticals Corporation | $505.27 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $414.74 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Acadia Pharmaceuticals INC | $397.91 | 2019-2025 | Nuplazid, Daybue |
| Emd Serono, INC. | $396.04 | 2019-2025 | Mavenclad |
| Lundbeck LLC | $351.83 | 2019-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $351.20 | 2019-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $329.35 | 2019-2025 | Tysabri, Vumerity |
| Amgen INC. | $328.45 | 2019-2023 | Aimovig |
| Allergan, INC. | $302.83 | 2019-2021 | |
| Pfizer INC. | $293.00 | 2022-2025 | |
| Mdd US Operations, LLC | $287.41 | 2019-2024 | Apokyn |
| Sk Life Science, INC. | $242.85 | 2020-2025 | |
| Genzyme Corporation | $216.54 | 2019-2022 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $211.31 | 2022-2025 | Xeomin, Inbrija |
| Kyowa Kirin, INC. | $197.28 | 2021-2025 | Nourianz |
| Adamas Pharmaceuticals, INC. | $192.18 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $191.65 | 2019-2021 | |
| Eisai INC. | $189.38 | 2019-2025 | |
| Medtronic USA, INC. | $163.50 | 2019 | |
| Amneal Pharmaceuticals LLC | $156.92 | 2019-2024 | Rytary, Ongentys |
| Medtronic, INC. | $150.81 | 2021-2025 | Percept PC Brainsense |
| Lilly USA, LLC | $134.94 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Genentech USA, INC. | $108.09 | 2019-2023 | Ocrevus |
| Alexion Pharmaceuticals, INC. | $107.84 | 2019-2023 | Ultomiris |
| Corium, LLC | $106.80 | 2022-2023 | Adlarity |
| Sumitomo Pharma America, INC. | $100.37 | 2023-2024 | Aptiom |
| Livanova USA, INC. | $100.20 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Mallinckrodt Enterprises LLC | $98.00 | 2019 | |
| Currax Pharmaceuticals LLC | $95.38 | 2021-2024 | Onzetra Xsail |
| Grifols USA, LLC | $90.11 | 2019-2024 | Gamunex-C |
| Argenx US, INC. | $67.86 | 2023-2025 | Vyvgart Hytrulo |
| Supernus Pharmaceuticals, INC. | $65.02 | 2020-2025 | Qelbree |
| Scilex Pharmaceuticals INC. | $61.56 | 2023-2025 | Ztlido |
| Azurity Pharmaceuticals, INC. | $60.67 | 2024-2025 | Horizant |
| Acorda Therapeutics, INC | $59.93 | 2019 | |
| Csl Behring | $56.56 | 2019-2023 | Hizentra |
| Ani Pharmaceuticals, INC. | $56.07 | 2023-2024 | Purified Cortrophin Gel |
| Ge Healthcare | $55.92 | 2022-2023 | |
| Celgene Corporation | $55.87 | 2024 | Zeposia |
| Impel Pharmaceuticals INC. | $45.30 | 2022-2023 | Trudhesa |
| Greenwich Biosciences, INC. | $42.67 | 2019 | |
| Merz North America, INC. | $40.46 | 2019 | |
| Upsher-Smith Laboratories LLC | $38.03 | 2020 | |
| Arbor Pharmaceuticals, INC. | $30.77 | 2019 | |
| Neurelis, INC. | $23.80 | 2023 | Valtoco |
| Almatica Pharma LLC | $23.38 | 2023 | Gralise |
| Avion Pharmaceuticals | $22.85 | 2022 | |
| Strongbridge US INC. | $22.64 | 2019 | |
| Jazz Pharmaceuticals INC. | $22.14 | 2022 | |
| Collegium Pharmaceutical, INC. | $21.84 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.32 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.89 | 2024 | Nuedexta |
| Tg Therapeutics, INC. | $16.07 | 2024 | |
| Janssen Pharmaceuticals, INC | $15.94 | 2022 | |
| Avanir Pharmaceuticals, INC. | $11.65 | 2020 | |
| Vertical Pharmaceuticals, LLC | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.